The risk of loco-regional recurrence in papillary thyroid cancer (PTC) patients ranges from 15-30%. However, the clinical significance of small-volume loco-regional recurrence detected by highly sensitive ultrasonography is unclear.
ease in many patients that would have previously been considered clinically to be without evidence of disease (4, 5) .
Detection of loco-regional recurrence often leads to biopsy with subsequent central and/or lateral neck dissections, a practice that stems from studies demonstrating poor clinical outcomes in patients that developed clinically apparent palpable disease recurrence in the neck (2, 6) . Careful neck dissections in experienced hands have been associated with short-term biochemical remission rates of 30 -50% (7) (8) (9) and acceptable rates of postoperative hypoparathyroidism and major nerve dysfunction. However, some patients required more than one neck surgery to achieve biochemical remission, and up to 9% had no malignancy identified on pathological examination of the resected specimens (7) .
While resection of large, clinically apparent loco-regional metastases often provides a clinical benefit, it remains unclear whether resection of persistent/recurrent small-volume disease identified using highly sensitive detection tools provides any meaningful clinical benefit. Furthermore, there is little data to suggest that an early surgical intervention would provide better long-term clinical results than a cautious observation approach, which reserves surgical resection for evidence of clinically significant disease progression. In fact, the current American Thyroid Association (ATA) guidelines allow for observation of abnormal LN less than 5-8 mm in smallest diameter with biopsy deferred unless there is documented growth or if the node threatens vital structures (4) . Furthermore, the guidelines recommend biopsy of suspicious LN greater than 5-8 mm in smallest diameter only "if a positive result would change management." Unfortunately, the lack of information regarding the natural history of suspicious LN identified by follow-up US makes it difficult to know when a positive result should change clinical management.
Therefore, this study was designed to describe the natural history of abnormal LN identified on routine surveillance neck US after thyroidectomy for PTC. Our goal was to determine how many of these abnormal LN increased in size over time, to describe the magnitude and rate of increase in size, and to identify specific ultrasonographic and clinical predictors of LN growth.
Subjects and Methods

Subjects
After obtaining approval from our institutional review board, we retrospectively reviewed the US reports of thyroid cancer patients who had at least one neck US study during their follow-up at Memorial Sloan-Kettering Cancer Center between August 1998 and June 2009. Of the reports initially reviewed, 282 patients with PTC had an abnormal LN identified on consecutive US studies. Of those patients, a total of 166 PTC patients demonstrating at least one cervical LN suspicious for malignancy and followed with serial US at Memorial Sloan-Kettering Cancer Center for more than 1 yr met the inclusion criteria and are the basis of this study. Reasons for exclusion included follow-up of less than a year in 61 patients, histology other than PTC in 20 patients, systemic therapy or previous external beam radiotherapy in 13 patients, and insufficient data in 22 patients.
Patients included in this study represent a selected group judged by our thyroid management team to be at low risk of rapid disease progression. At our center, patients with poorly differentiated histology, markedly PET-positive disease, a history of rapid disease progression, concern for potential complications from local invasion, LN more than 2 cm in size, or multiple 1-to 1.5-cm suspicious LN, are not routinely offered the option of active surveillance.
LN were classified as suspicious for malignancy using standard sonographic descriptive features that included LN shape, echogenicity, absence of hilum, presence of nodal calcifications, cystic changes, and hypervascularity (5). Size was defined as the largest diameter among the three dimensions provided. Echogenicity was characterized relative to strap muscles. LN detected in the thyroid bed were excluded because the distinction between thyroid bed nodules and thyroid bed LN is often difficult, and their natural history was recently described by our group (10). In 10 cases in which the LN were not clearly suspicious according to the initial US report, the sonographic images were reviewed by a physician with expertise in neck US (S.F. and A.B.).
US evaluation of neck LN
US examinations were performed according to our standard protocol as part of routine clinical care that includes grayscale and color Doppler US assessment of the cervical LN in all compartments. Examinations were performed by technologists and supervised by attending radiologists with expertise in thyroid cancer diagnosis and follow-up at our institution, who reviewed images in real time. The US studies were performed with Siemens Acuson Sequoia (Siemens Medical, Mountain View, CA) units using 8-to 15-MHz linear 15L8w transducers.
Laboratory studies
All Tg values were measured using the Dynotest-TgS immunoradiometric assay (Brahms, Inc., Berlin, Germany; functional sensitivity 0.6 ng/ml normalized to Certified Reference Material 457) and were confirmed using a Tg recovery assay (11) . TSH was measured using Advia Centaur two-site sandwich immunoassay (Bayer Corp., Tarrytown, NY). Anti-Tg antibodies were measured using Siemens Immulite 2500 Chemistry Analyzer. Tg, anti-Tg antibodies, and TSH values were collected with each US examination.
Clinical follow-up
Patients were usually followed every 6 months during the first year and at 6-to 12-month intervals thereafter at the discretion of the attending physician based on the clinical course of the disease, with Tg measurement on suppressive therapy and neck US done at those same time intervals. Patients were stratified according to the ATA classification into low, intermediate, and high risk of recurrence and were evaluated for their response to therapy, as previously described (4, 12) . Diagnostic whole-body scan with stimulated Tg measurement and other imaging studies were ordered at the discretion of the attending physician. Study entry was defined as the time of the first US showing suspicious LN. The study period was defined as the time from the study entry US to the last available US obtained as part of continued observation or immediately before salvage surgery in patients that subsequently underwent surgical resection of the abnormal LN.
Outcomes
The primary endpoint was LN growth during follow-up. Growth was defined as an increase of at least 3 mm in the largest dimension when compared with the size of the node at initial detection. A 3-mm increase was selected because this is the minimal size change that can be reproducibly determined by high-resolution US while minimizing operator-dependent differences (intraoperative and interoperative) in size assessment (13) . We chose to analyze the greatest dimension of included LN, because it is the size measurement most commonly used in clinical practice for decision making. It is of note that the ATA guidelines refer to the smallest LN dimension due to surgical considerations, because long and thin LN are difficult to locate during surgery. Secondary outcomes included an increase in size of more than 5 mm (judged to be a clinically significant increase in size), the need for central or lateral neck dissection (salvage surgery), administration of additional RAI therapy, external beam radiotherapy to the neck due to recurrent disease, or local complications related to LN enlargement (nerve damage, compression, or invasion to adjacent structures). LN characteristics and outcome are presented per patient unless otherwise specified.
Statistical methods
Continuous data are presented either as means and SD or median and ranges, as appropriate for each variable. Categorical comparisons were performed with Fisher's exact test. Analysis was performed using SPSS software (version 18.0.1; SPSS, Inc., Chicago, IL). A P value Յ0.05 was considered statistically significant. Univariate and multivariate analysis was performed for factors predictive of LN growth.
Results
Initial clinico-pathological characteristics
Patients were predominantly females (63%) with a median age of 41 yr and a median time of 3 yr between initial surgery and study entry (Table 1) . Initial therapy included total thyroidectomy in 96% of patients, with therapeutic central neck dissection in 44% and lateral neck dissection in 31%. Most patients had classical PTC (85%) and an intermediate risk of recurrence according to the ATA classification (77%). As expected, the vast majority of patients had received therapeutic RAI before study entry, with a median cumulative dose of 179 mCi. One third of the patients had a previous salvage neck dissection before study entry and were being followed for a second cervical recurrence. Thyroglobulin levels at study entry were generally low, with a median of 0.6 ng/ml (range Ͻ0.6 -392). This value did not include the patients who had interfering anti-Tg antibodies, which were present in 15% of the study population. b Response to therapy cannot be evaluated in the following cases: after lobectomy, presence of anti-Tg antibodies in the absence of structural disease, and in patients who did not undergo RAI ablation.
Ultrasonographic features of abnormal LN
All of the 166 patients had at least one suspicious LN with one or more abnormal sonographic features, 70% of patients having LN with two or more abnormal features and 25% having three or more abnormal features ( Table  2 ). The most common abnormalities were increased vascularity and calcifications, followed by cystic changes and round morphology. Seventy-six percent of patients had a LN larger than 1 cm (129 of 166) with a median size of 1.3 cm (range 0.5-2.7 cm) in largest diameter. Nearly all the suspicious LN included in this study were located in the lateral neck (99%).
Clinical endpoints
After a median follow-up of 3.5 yr (range 1-13 yr) and after a median of six US examinations (range 2-16), 20% (33 of 166) of patients demonstrated an increase in the size of the suspicious LN of at least 3 mm, and only 9% (15 of 166) had an increase of at least 5 mm (Table 3) . In 14% of patients (23 of 166), no suspicious LN was detected at the end of followup. The median rate of growth in the nodes showing structural progression was 1.5 mm/yr (range 0.6 -4.7 mm/yr). None of the patients had local complications (nerve injury or invasion into adjacent structures) related to the natural history of the abnormal LN, and there was no disease-related mortality during the study period.
Of the 33 patients with LN growth, 13 patients underwent fine-needle aspiration (FNA) biopsy that demonstrated PTC in eight cases, reactive changes in four cases, and nondiagnostic cytology in one case. In the subgroup of 15 patients with growth of at least 5 mm, seven patients had FNA, of which five were consistent with PTC, one was reactive, and one was nondiagnostic.
Of the 166 included patients, an ultrasonographically suspicious LN was cytologically proven to be PTC during the course of the study in 22 patients. The change in size over time for each of these cytologically proven PTC LN is shown in Fig. 1 . During the follow-up period, 18% increased more than 5 mm (range 7-9 mm). As can be seen from Fig. 1 , only three of the LN increased to more than 2 cm during the first 1-3 yr of follow-up and were surgically removed (also see Fig. 2 ).
Distant metastases were present in 13 of 166 patients included in the study. The distant metastases were known at study entry in 12 patients. One patient had multiple small non-RAI-avid, non-F-18 fluorodeoxyglucose (FDG)-avid pulmonary nodules diagnosed by chest computed tomography 7 months after study entry, which remained stable during the subsequent 8 yr of follow-up. Distant metastases were not identified in any other patients during the follow-up period. 
Factors predictive of LN growth or resolution
Clinical and sonographic features that were potentially predictive of LN growth are presented in Table 4 . Patients with LN growth of at least 5 mm were more likely to have FDG-avid LN, to have smaller LN at study entry, to be males, and to have an increase in Tg of more than 0.5 ng/ml during the study period (even though only 20% of patients demonstrated a Tg increase coincident with or before enlargement of the abnormal LN) (see Table 4 ). Of the sonographic features, only increased vascularity was significantly more common in the growing LN (10 of 15 vs. 50 of 133, P ϭ 0.04). The number of abnormal features was not predictive of LN growth. From a clinical standpoint, none of the clinical or sonographic features had a high enough positive predictive value to reliably determine which nodules are likely to grow (range 0.21-0.57). Patients in which no abnormal LN was detected on the last US were less likely to present with hypervascular LN (P ϭ 0.03), and more likely to have LN with detectable hilum on initial US (P ϭ 0.05). It is interesting to note that even in this group, several LN had clearly abnormal features, including calcifications (seven patients) and cystic changes (three patients). b Total number of patients with FDG-avid LN ϭ 19.
c Thyroid bed nodules are masses found on US in the neck area where the thyroid was located.
Salvage therapy
Twenty-four patients (14%) were treated with RAI during the study period with a median dose of 255 mCi, of which four (16%) nodes grew at least 3 mm. All treatments were given shortly after detection of the suspicious LN (median time to treatment of 4 months, range 1-12 months) and before documented increase in size of the suspicious LN. Salvage neck dissection was performed in 22 patients (13%) after a median follow-up of 2.5 yr (range 1-10 yr). Only nine patients (43%) were operated due to LN growth, whereas others had other indications (thyroid bed nodule growth, positive PET, or positive FNA). After surgery, all cases were pathologically confirmed as metastatic PTC, and of 18 patients with a measurable Tg level before removal of the suspicious LN, three (17%) achieved a Tg less than 0.6 ng/ml on suppression postoperatively. Three patients had complications from surgery (three of 21, 14%), two with postoperative accessory nerve dysfunction and one with a chyle leak, of which only one had LN growth before surgery. To evaluate whether the abnormal nodes taken out during surgery invaded adjacent structures, we reviewed all the surgical and pathological reports and found no evidence of significant invasion.
Discussion
To the best of our knowledge, this is the first study to describe the natural history of suspicious cervical LN identified after initial therapy for PTC and followed with serial US examinations for several years. After a median follow-up of 3.5 yr, a 3-mm or more increase in the size of the suspicious LN was seen in 20% of patients and in only 9% of patients demonstrating a growth of 5 mm or more. Patients who had an increase in LN size demonstrated a slow rate of growth of 1.5 mm/yr, with no evidence of local complications. These findings suggest that most patients with a small number of suspicious LN in the 1-to 2-cm range in the lateral neck can be followed with observation without routine FNA using an approach similar to that recommended by the updated ATA guidelines for management of small (5-8 mm in shortest dimension) abnormal cervical LN (recommendation 48c) (4). This recommendation is most applicable to relatively young patients (median age of 41 yr) after total thyroidectomy and RAI ablation for PTC without high-risk features. Furthermore, these data are consistent with our previous findings that demonstrated most sub-centimeter thyroid bed nodules also remained stable over years of follow-up (10) .
Although a definitive cytological or histology diagnosis was not available on the majority of the suspicious LN followed during the study, the selection criteria for study entry is very likely to have enriched in the study set in malignant LN. The high number of abnormal features (70% with two or more features), the relative specificity of the most common features for malignancy (hypervascularity, calcifications, and cystic changes), the size of the nodes (78% 1 cm or larger), and their persistence over time strongly suggests that many of these abnormal LN were malignant (5, 14, 15) . It is important to remember that the goal of this study was to describe the natural history of suspicious LN (not necessarily malignant LN). However, since we did have a subgroup of 22 patients with cytologically proven LN metastases followed with observation, we were able to show that clinically significant disease progression was seen in only a minority (18%) of the patients selected for active surveillance.
Our results argue that immediate resection of metastatic cervical LN is not required in many patients with recurrent PTC. Since we usually reserve surgical resection of suspicious LN for those few cases that demonstrate clinically significant growth, we do not routinely advocate FNA biopsy of these LN because the results would not significantly alter our clinical management. This active observation approach is an attractive alternative to immediate surgical resection because several previous studies have demonstrated biochemical cure rates of only 30 -50% after repeat neck surgery (7) (8) (9) , with some patients requiring more than one surgery to achieve remission. Furthermore, up to 9% of patients will have no malignancy on the pathological examination of the surgically resected LN despite having biopsy-proven LN metastases preoperatively (7, 8) . Although repeated neck surgeries can be performed relatively safely in expert hands, each surgery carries significant risk for complications (including nerve damage, hypoparathyroidism, chyle leak, neck pain, and more).
Since the majority of suspicious LN remain stable for many years, it would have been clinically useful to identify clinical or ultrasonographic characteristics predictive of growth. Unfortunately, while several parameters were statistically associated with growth of the suspicious LN (male gender, FDG avidity, hypervascularity, and Tg rise during follow-up), none of them had a high enough positive predictive value to be clinically useful. Even the suppressed Tg value, which is generally considered to be a reliable marker of disease progression, demonstrated a significant increase in only 20% of the patients that had a increase in LN size of 5 mm or more during follow-up. There was no correlation between cumulative RAI dosage and the risk of LN growth, but we could not determine whether LN stability was due to intrinsic tumor characteristics, previous RAI therapy, or ongoing TSH suppression. Therefore, serial US evaluations at 6-to 12-month intervals are required to identify the few patients that will eventually demonstrate significant disease progression. One of the driving forces for surgical resection of suspicious LN is the concern that adverse outcomes will occur if the disease is not resected. However, our data demonstrate that a cautious observation approach is very safe in properly selected patients with suspicious cervical LN. In our cohort, none of the patients developed side effects associated with an increase in the size of the suspicious LN, and none of the patients developed progressive distant metastasis during the relatively short follow-up period.
Our work has several limitations. Most importantly, the patients included in this study represent a selected group of patients chosen for follow-up by the treating physicians. These patients typically had initial surgery in which all macroscopic disease was removed, did not have extensive lymphadenopathy, and did not have rapidly progressive disease. As per our routine practice patterns, patients with suspicious LN that were judged by the thyroid management team to be at risk for rapid progression (poorly differentiated histology, FDG PET positive, a history of rapid disease progression, concern for potential complications from local invasion, LN larger than 2 cm and multiple 1-to 1.5-cm LN) would have been sent for surgical resection and would not have been included in this study. Therefore, it is likely that the findings of this study are most generalizable to patients with well-differentiated thyroid cancer, with a small number of 1-to 2-cm suspicious LN in the lateral neck. Second, although the US studies were performed by a limited group of experienced radiologists at a specialized center, operator-dependent variation in size measurements of LN is an intrinsic variable of US images review that we were unable to control. However, the criterion for growth (Ն3 mm in largest diameter) was intentionally chosen to minimize the impact of these variations. Third, management decisions were made by individual treating physicians based on the specific characteristics of each patient, which may have had a significant impact on the types and quantity of data available for analysis. Additional randomized controlled trials are needed to compare our active surveillance strategy vs. early surgical intervention. Finally, even though it is reassuring that immediate surgical resection is not always required when suspicious LN are identified, the long-term natural history of these suspicious LN over 10 -20 yr still needs to be studied because our follow-up period was relatively short.
Conclusion
Suspicious LN detected during routine follow-up of selected PTC patients after thyroidectomy often remain stable for long periods of time and are very unlikely to cause local complications or be associated with the development of distant metastases if followed carefully with serial US examinations. Active surveillance using serial US evaluations at 6-to 12-month intervals appears to be a very reasonable approach to management of small number of suspicious lateral neck LN identified during routine follow-up of patients with PTC. Biopsy and subsequent surgical intervention can be reserved for the small number of patients that demonstrated clinically significant disease progression during follow-up.
